MyMyelomaTeam

Is your rising lambda light chain level large enough to indicate relapse requiring a maintenance change?

The rising trend in your lambda light chain levels—from normal range to 60—is concerning and warrants immediate discussion with your hematologist-oncologist. While this upward pattern could signal early relapse, your Show Full Answer

Is your rising lambda light chain level large enough to indicate relapse requiring a maintenance change?

The rising trend in your lambda light chain levels—from normal range to 60—is concerning and warrants immediate discussion with your hematologist-oncologist. While this upward pattern could signal early relapse, your doctor will need to evaluate additional factors before confirming a diagnosis or changing your maintenance therapy.

A relapse is typically diagnosed based on multiple criteria, not just one marker. Your doctor will likely look for:

• Increased plasma cells in bone marrow
• Higher levels of M protein or serum-free light chains
• New or growing bone lesions or plasmacytomas
• Signs of CRAB criteria (high Calcium, Renal impairment, Anemia, Bone disease)

Your oncologist may order comprehensive testing including blood work, bone marrow biopsy, and imaging to determine if these rising lambda levels represent true disease progression or just fluctuation. Minimal residual disease (MRD) testing can also help assess whether myeloma cells are increasing.

If relapse is confirmed, your treatment plan will be reevaluated. The good news is that if you relapse more than six months after starting a treatment, your doctor may consider using the same therapy again or adjusting to a different combination based on your response.

Don't wait for your next scheduled appointment—contact your care team now to discuss these results and determine next steps.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Myeloma Relapse Rates and 9 Treatment Options for Relapses

6 Refractory Myeloma Treatment Options: First Line, CAR T Cells, and More